Biotech Values

[corpstrat]

Your repeatedly shrill tone invites a response in kind at last. Can you read? Let me spell it out for you.

I agree with you that the cost-benefit of Avastin is unacceptable. But what I suggested was that at least DNA spends some of the exorbitant revenue haul on top science, which presumably is not designed to arrive at a mediocre therapy from a C-B perspective, and has a better chance than most programs of valuable breakthroughs. Under new mgt, the revenue haul will not shrink in the early years, but the science that it buys will deteriorate markedly. As a society, we'll have much less to show in R&D output for the excess spending on Avastin. OK?